GBI selects Nokia to build new network for faster, more resilient connectivity across the Middle East

(Helsinki:NOKIA),(Irish:IRSH),(LSE:0HAF),(Paris:NOKIA), Press ReleaseGBI selects Nokia to build new network for faster, more resilient connectivity across the Middle East GBI's new network with Nokia will enhance its regional optical infrastructure with state-of-the-art technology that supports faster, more reliable access to digital services. The new scalable and low-latency network will offer 100G-400G services that boost network resilience […]

GBI selects Nokia to build new network for faster, more resilient connectivity across the Middle East

GBI selects Nokia to build new network for faster, more resilient connectivity across the Middle East GlobeNewswire October 22, 2025 Press ReleaseGBI selects Nokia to build new network for faster, more resilient connectivity across the Middle East GBI's new network with Nokia will enhance its regional optical infrastructure with state-of-the-art technology that supports faster, more

Boliden Q3 2025: Strong cash flow and solid mine production

“Overall, the results for the quarter were strong. We had a significant cash flow, even though major investments are still ongoing primarily in theBoliden Area, Odda and Rönnskär.”- Mikael Staffas, President and CEO. Financials — Revenues: SEK 21,971 m (22,193) — Operating profit: SEK 3,237 m (3,165) — Operating profit excl. PIR*: SEK 2,752 m

Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance

(Paris:IPN), Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo(R), Bylvay(R) and Somatuline(R) Further upgrade of full-year 2025 financial guidance based on slower than anticipated erosion of Somatuline(R) and accelerated sales growth of the rest of the portfolio: total sales

Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance

Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance GlobeNewswire October 22, 2025 Year-to-date total sales growth of 12.1% at CER1, or 9.6% as reported, driven by all three therapeutic areas and including strong performance from Iqirvo(R), Bylvay(R) and Somatuline(R) Further upgrade of full-year 2025 financial guidance

Teck Reports Unaudited Third Quarter Results for 2025

(TSX:TECK.A),(TSX:TECK.B),(TSX:TECK-A),(TSX:TECK-B),(NYSE:TECK), VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (Teck) today announced its unaudited third quarter results for 2025. “The merger of equals between Teck and Anglo American announced this quarter is a unique opportunity to create a global leader in critical minerals and a

Teck Reports Unaudited Third Quarter Results for 2025

Teck Reports Unaudited Third Quarter Results for 2025 Merger of equals to create new global critical minerals champion and unlock substantial value GlobeNewswire October 22, 2025 VANCOUVER, British Columbia, Oct. 22, 2025 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (Teck) today announced its unaudited third quarter results for 2025. “The

Ubisoft Singapore Elevates Game Audio with Neumann Studio Monitors

Studio Blue sets new benchmarks for game audio production Ubisoft Singapore, a leading AAA game development studio in Southeast Asia, has recently outfitted its newly upgraded Studio Blue with Neumann studio monitors which belongs to Sennheiser Group to support advanced audio production workflows. As the first Dolby Atmos-enabled game development sound studio in Southeast Asia,

Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline

(Paris:IPN), Acquisition focused on lead clinical-stage program ICT01 in acute myeloid leukemia, where data from the ongoing Phase I/II EVICTION trial showed high treatment response ICT01 has the potential to be a new standard of care in combination in first line unfit acute myeloid leukemia, an aggressive blood cancer affecting older adults Ipsen to acquire

Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

(Paris:SAN), Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus a standard of care plasma-derived therapy Results reinforce the potential of efdoralprin alfa to be the first restorative recombinant therapy that normalizes and maintains functional AAT levels

Scroll to Top